In Phase I clinical trials, a potential drug is tested for the first time in human subjects, usually healthy volunteers. The primary objective is make assessments about drug safety. Clinicians also learn more about the mode of action of a potential drug and how it is absorbed, distributed, metabolized, and excreted by the body.
MT203
PDE4 inhibitor
| Project |
MT203 is a human antibody which neutralizes granulocyte macrophage colony-stimulating factor (GM-CSF), a cytokine known to play a significant role in auto-immune and inflammatory diseases. |
| Therapeutic area |
Inflammatory and auto-immune disesases |
| Partner |
Joint development with Micromet
Exclusive worldwide collaboration to develop and commercialize anti-GM-CSF antibodies for the treatment of inflammatory and autoimmune diseases. |
| News |
24.05.2007: Nycomed and Micromet Enter Into Exclusive Worldwide Collaboration |
| Project |
Phosphodiestrase-4 (PDE4) is known to be promising target in inflammatory and respiratory diseases. With the PDE4 inhibitor compound, we build on on our existing expertise in this area. |
| Therapeutic area |
Inflammation, Respiratory |